Health Care and Biotech

Mayne Pharma’s results suggest a rocky first half has been overcome. Brokers are optimistic on the outlook.

Sonic Healthcare has shelved a challenging year with brokers finding the outlook both reasonable and achievable.

In this week’s Weekly Highlights: – Domestic Reporting Season Thus Far – Death To The Death Cross – Everybody Loves…

Michael Gable of Fairmont Equities suggests the risk remains to the downside for Ansell following the company’s weak result.

Sirtex Medical is making steady progress but brokers consider the stock to be a longer-term investment opportunity.

AirXpanders has developed a major improvement in the technology used in breast reconstruction and Canaccord Genuity initiates coverage.

Diagnostic imaging operator, Capitol Health, is in robust form heading into FY16, supported by demographics and low competitive tension.

Capitol Health is on a strong growth path, supported by acquisitions and an increasingly preventative approach to medicine.

FY15 results likely flat; FTA TV structurally challenged long term; mobile competition high; Macquarie ranks funds managers; Oz retailers; key oncology stocks.

A decision by the US National Comprehensive Cancer Network to recommend breast cancer patients be monitored for lymphoedema is considered a boost to Impedimed’s prospects.